Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) AI Stock Analysis

• Market Cap: HK$1.32B
• Dividend Yield: 2.93%
• Average Volume (3M): 96.19K
• Price to Earnings (P/E): 6.6
• Beta (1Y): 0.36
• Revenue Growth: 2.82%
• EPS Growth: 21.63%
• Country: HK
• Employees: 745
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): N/A
• Shares Outstanding: 172,500,000
• 10 Day Avg. Volume: 162,580
• 30 Day Avg. Volume: 96,193
• PEG Ratio: 0.48
• Price to Book (P/B): 0.67
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$2.47
• Price Target Upside: 4.85% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 0

• Rating: 78 Outperform
• Price Target: HK$2.50 ▲(5.93%Upside)

The overall stock score is primarily driven by strong financial performance with consistent revenue growth and solid margins. The technical analysis supports a positive outlook, although overbought signals suggest caution. The stock's undervaluation offers potential investment upside.

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Business Overview & Revenue Model

Company Description

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H (8049) is a China-based company primarily engaged in the research, development, manufacturing, and distribution of pharmaceutical products. The company operates within the health care sector, focusing on a wide range of medicinal products, including both traditional Chinese medicines and modern pharmaceuticals. These products are designed to address various health concerns and improve the overall well-being of consumers.

How the Company Makes Money

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. generates revenue through the sale of its pharmaceutical products both domestically and internationally. The company's key revenue streams include the production and distribution of traditional Chinese medicines, modern pharmaceuticals, and health supplements. Sales are made through various channels, including hospitals, pharmacies, and direct sales to consumers. Additionally, the company may engage in collaborations or partnerships with other pharmaceutical entities to expand its product offerings and market reach. Factors contributing to its earnings include the demand for healthcare products, regulatory approvals, and the company's ability to innovate and develop new treatment solutions.

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Financial Statement Overview

Summary

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H has demonstrated strong financial performance with consistent revenue and profit growth, robust margins, and a stable financial structure. The company maintains a low debt-to-equity ratio and a solid equity base, although there is a noted decrease in free cash flow growth.

Income Statement

The company has demonstrated consistent revenue growth with a revenue growth rate of 4.7% in 2024, while maintaining strong profitability margins. Gross profit margin stands at 77.8% and net profit margin at 20.9% in 2024, reflecting efficient cost management and solid earnings. The EBIT margin of 23.7% and EBITDA margin of 26.8% further highlight strong operational performance.

Balance Sheet

The balance sheet is robust with a low debt-to-equity ratio of 0.04, indicating minimal leverage and financial risk. The company has a healthy equity ratio of 64.4%, showcasing strong equity financing. Return on equity is solid at 11.3%, indicating effective utilization of shareholder funds. The financial stability is bolstered by a significant cash reserve.

Cash Flow

The company exhibits strong cash flow generation with a free cash flow of 208.6 million. However, the free cash flow decreased by 26.6% from the previous year due to a reduction in operating cash flow. The operating cash flow to net income ratio of 1.19 indicates robust cash conversion, while the free cash flow to net income ratio of 1.13 underscores effective capital expenditure management.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	881.16M	841.54M	841.59M	705.46M	622.25M
Gross Profit	685.25M	584.05M	648.03M	580.00M	530.74M
EBITDA	236.33M	226.39M	231.43M	206.50M	172.92M
Net Income	184.25M	148.21M	193.56M	143.28M	126.56M
Balance Sheet
Total Assets	2.53B	2.32B	2.37B	2.07B	1.80B
Cash, Cash Equivalents and Short-Term Investments	539.03M	655.59M	1.03B	262.25M	242.94M
Total Debt	72.40M	80.40M	400.00K	400.00K	400.00K
Total Liabilities	901.49M	838.44M	760.54M	618.56M	459.02M
Stockholders Equity	1.63B	1.48B	1.61B	1.45B	1.35B
Cash Flow
Free Cash Flow	208.63M	284.11M	192.68M	122.25M	52.46M
Operating Cash Flow	219.65M	315.95M	203.99M	215.09M	151.23M
Investing Cash Flow	-310.93M	109.04M	-117.97M	-160.61M	-244.85M
Financing Cash Flow	-25.01M	-186.45M	-27.71M	-25.20M	-17.75M

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.36
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:8049, the sentiment is Positive. The current price of 2.36 is above the 20-day moving average (MA) of 2.17, above the 50-day MA of 2.05, and above the 200-day MA of 1.51, indicating a bullish trend. The MACD of 0.06 indicates Negative momentum. The RSI at 65.62 is Neutral, neither overbought nor oversold. The STOCH value of 91.90 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:8049.

Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2161	79 Outperform	HK$2.48B	12.67	19.22%	3.13%	18.06%	80.57%
8049	78 Outperform	HK$1.32B	6.62		2.93%	2.82%	21.63%
2348	73 Outperform	HK$2.04B	3.29	18.33%	5.33%	-9.95%	67.56%
3737	70 Outperform	HK$686.07M	6.63	8.81%	7.18%	5.79%	-43.49%
0950	65 Neutral	HK$924.47M	10.12	5.04%	2.87%	32.95%	456.69%
Sector *	60 Neutral	HK$17.07B	6.10	-7.44%	2.88%	11.55%	-28.15%
1652	46 Neutral	HK$246.30M	―	-40.39%	―	-43.73%	-434.56%